$AZTRAug 12, 2026, 5:00 PM ETAI processed
Azitra Q2: ATR‐COSF shows ex‐vivo anti‐wrinkle activity; ATR‐04 enrollment continues, topline Q4'26
AI Summary
Azitra reported Q2 results and disclosed positive preclinical ex vivo human skin data for ATR‐COSF showing repeat‐dose delivery, targeted skin‐layer distribution and anti‐wrinkle activity, supporting advancement toward a planned proof‐of‐concept cosmetic study (human study planned Q3 2026). The company said it is continuing enrollment of the first cohort in the Phase 1/2 ATR‐04 trial for EGFR inhibitor‐associated rash across six sites including MD Anderson with topline cohort data expected in Q4 2026, is advancing recombinant protein initiatives (TEV protease, T7 RNA polymerase), paused further enrollment in the ATR‐12 Phase 1b study to focus capital, and finished the quarter with $6.7M cash and a $3.3M net loss.
Positives
- Positive ATR‑COSF preclinical ex vivo human skin data showing repeat‑dose delivery and anti‑wrinkle activity; human cosmetic study planned Q3 2026
- ATR‑04 Phase 1/2 first cohort enrollment ongoing at six sites (including MD Anderson); topline data expected Q4 2026
- Advancing recombinant protein platform (TEV protease, T7 RNA polymerase) to expand commercial applications
Negatives
- Net loss of $3.3M for Q2 2026 and accumulated deficit of $75.8M
- Paused further enrollment in ATR‑12 Phase 1b for Netherton syndrome, reducing near‑term development breadth
- Cash and cash equivalents $6.7M as of June 30, 2026 (limited visibility on runway)